NANOG and neoplasm: These results suggest that NANOG–HSP90A axis could be responsible for resistance to anti-PD-1 therapy, and HSP90A inhibition overcomes NANOG–HSP90A axis-mediated resistant phenotype of tumor cells to immunotherapy.